Pfizer’s Lyrica Gets Split Decision As FDA Raises The Formulation Bar For Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
With Pfizer’s blockbuster pain drug facing numerous generic challengers, the pharma gets FDA to agree not to accept any pregabalin ANDA that would include a “not less than” minimum level for R-isomer impurities; Pfizer’s patent certification arguments fall flat, however.
You may also be interested in...
Q&A: Renalytix AI Prez Explains How MCIT Rule Will Aid Kidney Product Coverage By CMS
Tom McLain tells how the new MCIT policy from the US Medicare agency – and winning support from Congress – will guarantee Medicare coverage for his company’s product, an artificial intelligence-enabled in vitro diagnostic platform.
Bridges Consumer Startup Reaches Brands For Specialty Conditions In Clarion Deal
Acquiring Clarion Brands from Swander Pace, Bridges Consumer Healthcare adds portfolio of OTC and supplement brands for symptoms including tinnitus, urinary pain relief and excessive sweating.
MDIC Proposes Real-World Evidence Framework For Sponsors To Hasten Their Product Application
The document from the Medical Device Innovation Consortium aggregates external data sources, various statistical methods and lays out other considerations for sponsors to help speed up and bolster a premarket product application to the US FDA.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: